Calcium Hydroxylapatite-Based Fillers in Facial Rejuvenation: A Prospective, Single-Center, Unblinded Comparative Outcome Study of Radiesse® vs. Rennova® Diamond Intense
Journal of Clinical Medicine · 09.06.2025 · 14 (12) · 4072
DOI: 10.3390/jcm14124072 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 09.06.2025. Verfasst von Bruna S F Bravo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Bravo Private Clinic, Rio de Janeiro 22440-032, Brazil. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Rennova®️, Rennova®.
Abstract (Originalsprache)
Background/Objectives: Calcium hydroxylapatite (CaHA)-based dermal fillers are widely used in esthetic medicine due to their dual volumizing and biostimulatory properties. Despite their rising popularity, comparative clinical outcome data evaluating different CaHA fillers remain limited. This prospective, single-center, unblinded study aimed to establish the effectiveness of the CaHA filler Rennova® Diamond Intense via comparison to the well-established CaHA filler Radiesse® in terms of clinical performance, safety, and patient satisfaction.
Methods
Thirty patients (28 female, 2 male) underwent a single-session bilateral injection of Rennova® Diamond Intense (right side) and Radiesse® (left side) in the lower and medial posterior facial regions. Outcomes evaluated at multiple time points included dermal thickness, skin elasticity, transepidermal water loss, patient-reported outcomes (S-GAIS), physician-assessed outcomes (P-GAIS), and adverse events.
Results
Both fillers showed improvements across all parameters. Patient-reported S-GAIS indicated predominantly “improved” outcomes at days 60 and 120, whereas physician assessments (P-GAIS) predominantly indicated “very improved” results at day 120. Ultrasound revealed increases in dermal thickness for both fillers. Similarly, improvements in skin elasticity and decreases in transepidermal water loss were observed bilaterally. Mild, transient adverse events (pain, swelling, redness, bruising) resolved spontaneously within 30 days post injection.
Conclusions
Rennova® Diamond Intense effectively increases dermal thickness, improves skin elasticity, and reduces transepidermal water loss, achieving high patient and physician satisfaction. These findings underscore its safety, versatility, and efficacy for esthetic facial rejuvenation, warranting further long-term evaluation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Bravo Private Clinic, Rio de Janeiro 22440-032, Brazil.
- Innovapharma Brasil Farmaceutica Ltda, São Paulo 04578-910, Brazil.
ORCID-Profile: Bruna S F Bravo
Förderung
- Rennova®️
- Rennova®
Zitieren
APA
Bravo, B. S. F., Bravo, L. G., Gouvea, B. F., Neves, M. R. B., Nobre, C. S., Silva, C. D. S., & do Nascimento, C. M. O. L. (2025). Calcium Hydroxylapatite-Based Fillers in Facial Rejuvenation: A Prospective, Single-Center, Unblinded Comparative Outcome Study of Radiesse® vs. Rennova® Diamond Intense. Journal of Clinical Medicine, 14(12), 4072. https://doi.org/10.3390/jcm14124072
Vancouver
Bravo BSF, Bravo LG, Gouvea BF, Neves MRB, Nobre CS, Silva CDS, et al. Calcium Hydroxylapatite-Based Fillers in Facial Rejuvenation: A Prospective, Single-Center, Unblinded Comparative Outcome Study of Radiesse® vs. Rennova® Diamond Intense. Journal of Clinical Medicine. 2025;14(12):4072. doi:10.3390/jcm14124072
BibTeX
@article{Bravo2025,
author = {Bravo, Bruna S F and Bravo, Leonardo G and Gouvea, Bárbara F and Neves, Marina R B and Nobre, Camila S and Silva, Camila D S and do Nascimento, Carolina Machado Ozório Lopes},
title = {Calcium Hydroxylapatite-Based Fillers in Facial Rejuvenation: A Prospective, Single-Center, Unblinded Comparative Outcome Study of Radiesse® vs. Rennova® Diamond Intense},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {12},
pages = {4072},
doi = {10.3390/jcm14124072}
}
EUVIMED